Confo Therapeutics

TLDR

Confo Therapeutics is a Ghent-based VIB spin-off developing GPCR-targeted drugs using proprietary conformational antibody technology, having raised EUR 60M in a Series B led by Ackermans and van Haaren in July 2024.

Overview

Founded as a spin-off from VIB, the Flemish Institute for Biotechnology, Confo Therapeutics is based in Ghent and focuses on GPCRs (G protein-coupled receptors), a class of targets implicated in a wide range of diseases. GPCRs are notoriously difficult to work with in drug discovery because they are unstable outside their natural membrane environment.

Confo's proprietary conformational antibody technology stabilizes GPCRs in their biologically relevant shapes, enabling structural studies and drug screening that would otherwise be impossible. This platform has the potential to unlock new drug targets across cardiovascular, neurological, metabolic, and oncological diseases.

The EUR 60M Series B was led by Ackermans and van Haaren in July 2024, an unusual direct lead from a Belgian industrial holding company into a biotech drug discovery platform. The round validates both the scientific approach and the commercial potential of the Confo technology.

Funding History

• Series B: EUR 60M (July 2024), led by Ackermans and van Haaren. See Confo Therapeutics Series B 2024.